Evidence of Misclassification of Drug-Event Associations Classified as Gold Standard 'Negative Controls' by the Observational Medical Outcomes Partnership (OMOP)
- PMID: 26879560
- DOI: 10.1007/s40264-016-0392-2
Evidence of Misclassification of Drug-Event Associations Classified as Gold Standard 'Negative Controls' by the Observational Medical Outcomes Partnership (OMOP)
Abstract
Introduction: Pharmacovigilance includes analysis of large databases of information on drugs and events using algorithms that detect disproportional frequencies of associations. In order to test such algorithms, attempts have been made to provide canonical reference lists of so-called 'positive controls' and 'negative controls'. Reference sets with even modest levels of misclassification may result in under- or overstatement of the performance of algorithms.
Aim: We sought to determine the extent to which 'negative control' drug-event pairs in the Observational Medical Outcomes Partnership (OMOP) database are misclassified
Methods: We searched the medical literature for evidence of associations between drugs and events listed by OMOP as negative controls.
Results: The criteria used in OMOP to classify positive and negative controls are asymmetric; drug-event associations published only as case series or case reports are classified as positive controls if they are cited in Drug-Induced Diseases by Tisdale and Miller, but as negative controls if case series or case reports exist but are not cited in Tisdale and Miller. Of 233 drug-event pairs classified in the 2013 version of OMOP as negative controls, 21 failed to meet pre-specified OMOP adjudication criteria; in another 19 cases we found case reports, case series, or observational evidence that the drug and event are associated. Overall, OMOP misclassified, or may have misclassified, 40 (17 %) of all 'negative controls.'
Conclusions: Results from studies of the performance of signal-detection algorithms based on the OMOP gold standard should be viewed with circumspection, because imperfect gold standards may lead to under/overstatement of absolute and relative signal detection algorithm performance. Improvements to OMOP would include omitting misclassified drug-event pairs, assigning more specific event labels, and using more extensive sources of information.
Similar articles
-
A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance.Drug Saf. 2015 Aug;38(8):749-65. doi: 10.1007/s40264-015-0297-5. Drug Saf. 2015. PMID: 26055920
-
A Comparison Study of Algorithms to Detect Drug-Adverse Event Associations: Frequentist, Bayesian, and Machine-Learning Approaches.Drug Saf. 2019 Jun;42(6):743-750. doi: 10.1007/s40264-018-00792-0. Drug Saf. 2019. PMID: 30762164
-
A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases.Drug Saf. 2013 Jan;36(1):13-23. doi: 10.1007/s40264-012-0002-x. Drug Saf. 2013. PMID: 23315292
-
[Drug-induced pancreatitis. A review of French spontaneous reports].Rev Med Interne. 2015 Sep;36(9):573-8. doi: 10.1016/j.revmed.2015.04.012. Epub 2015 Jun 1. Rev Med Interne. 2015. PMID: 26045335 Review. French.
-
Using real-world healthcare data for pharmacovigilance signal detection - the experience of the EU-ADR project.Expert Rev Clin Pharmacol. 2015 Jan;8(1):95-102. doi: 10.1586/17512433.2015.992878. Expert Rev Clin Pharmacol. 2015. PMID: 25487079 Review.
Cited by
-
An MCEM Framework for Drug Safety Signal Detection and Combination from Heterogeneous Real World Evidence.Sci Rep. 2018 Jan 29;8(1):1806. doi: 10.1038/s41598-018-19979-7. Sci Rep. 2018. PMID: 29379048 Free PMC article.
-
A Drug Similarity-Based Bayesian Method for Early Adverse Drug Event Detection.Drug Saf. 2025 Aug;48(8):923-931. doi: 10.1007/s40264-025-01545-6. Epub 2025 Apr 22. Drug Saf. 2025. PMID: 40261506 Free PMC article.
-
Leveraging the Variability of Pharmacovigilance Disproportionality Analyses to Improve Signal Detection Performances.Front Pharmacol. 2021 May 28;12:668765. doi: 10.3389/fphar.2021.668765. eCollection 2021. Front Pharmacol. 2021. PMID: 34122089 Free PMC article.
-
Measuring Signal Detection Performance: Can We Trust Negative Controls and Do We Need Them?Drug Saf. 2016 May;39(5):371-3. doi: 10.1007/s40264-016-0407-z. Drug Saf. 2016. PMID: 26895343 Review. No abstract available.
-
Toward multimodal signal detection of adverse drug reactions.J Biomed Inform. 2017 Dec;76:41-49. doi: 10.1016/j.jbi.2017.10.013. Epub 2017 Nov 1. J Biomed Inform. 2017. PMID: 29081385 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical